2026 Interim Report
Filed with HKEX · Stock code 1477 · · 74 pages · English
Ocumension Therapeutics on 6ix
Earlier from Ocumension Therapeutics
- OcuMension acquires rights to Alcon eye drops in exchange for a 16.7% equity stake, signaling the commencement of comprehensive strategic relationship
- OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth
- Ocumension Therapeutics Announces 2023 Interim Results
- Ocumension Therapeutics Announces 2022 Annual Results
- Inside information new drug application of our core product OT-401 approved by the national medical products administration
Later from Ocumension Therapeutics
- Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2026
- Inside information announcement topline results of the Month 36 primary analysis of the global multi-centre phase III clinical trial of OT-101 (0.01% atropine sulfate eye drops)
- Voluntary announcement NMPA approval for localized production of fluocinolone acetonide intravitreal implant
- Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 October 2026
Follow Ocumension Therapeutics into a list and get an email when it puts out news.
Follow Ocumension Therapeutics